Overview
- President Trump signed executive actions that instruct agencies to speed research and access to psychedelic treatments for severe mental illness.
- FDA and the Department of Veterans Affairs must share data and boost clinical trial enrollment to move studies forward more quickly.
- The plan ties any federal rescheduling of psychedelics to FDA marketing approval on a case-by-case basis and introduces priority review vouchers for select drugs.
- The orders set aside $50 million for states building psychedelic programs and open paths for ibogaine studies and limited Right to Try access for the very ill.
- Cannabis is directed to Schedule III only for FDA-approved or state-licensed medical products, leaving recreational use unchanged under federal policy.